NCT06246552View on ClinicalTrials.gov

Clinical Trial to Evaluate the Safety and Efficacy of JTM201 to Treat Moderate or Severe Glabellar Lines

PHASE2CompletedINTERVENTIONAL
Enrollment

480

Participants

Timeline

Start Date

October 26, 2024

Primary Completion Date

June 5, 2025

Study Completion Date

June 5, 2025

Conditions
Glabellar Lines
Interventions
BIOLOGICAL

JTM201

"JTM201 20U in 0.5mL~: JTM201 will be injected via IM in 5 glabellar location 0.1mL (4U / 0.1mL) at each location"

BIOLOGICAL

Placebo

"Placebo 20U in 0.5mL~: Placebo will be injected via IM in 5 glabellar location 0.1mL (4U / 0.1mL) at each location"

Trial Locations (1)

90266

Ablon Skin Institute & Research Center, Manhattan Beach

All Listed Sponsors
lead

Jetema USA Inc.

INDUSTRY

NCT06246552 - Clinical Trial to Evaluate the Safety and Efficacy of JTM201 to Treat Moderate or Severe Glabellar Lines | Biotech Hunter | Biotech Hunter